SB 202190: Selective p38 MAP Kinase Inhibitor for MAPK Pathway Research

Executive Summary: SB 202190 is a potent, cell-permeable, ATP-competitive inhibitor of p38α and p38β MAP kinases, with IC₅₀ values of 50 nM and 100 nM, respectively, under standard kinase assay conditions (pH 7.5, 25°C, 15 min) [APExBIO]. The compound exhibits high selectivity for p38 isoforms over other MAP kinases, demonstrated by a K_d of 38 nM for p38α in biochemical binding assays. SB 202190 suppresses phosphorylation of downstream substrates and reduces pro-inflammatory cytokine production in cell-based assays (Ponsioen et al., 2021). The inhibitor is insoluble in water but dissolves readily in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL), and is stable as a solid at -20°C. Its robust, reproducible activity in apoptosis assays and animal models has made SB 202190 a standard tool in MAPK pathway and translational disease research [see detailed review].

Biological Rationale

The mitogen-activated protein kinase (MAPK) pathway regulates cellular responses to stress, inflammation, and proliferative signals. p38 MAPKs are serine/threonine kinases activated by environmental stress and inflammatory cytokines. The p38 pathway influences gene expression, cell cycle progression, apoptosis, and immune responses [Ponsioen et al., 2021]. In cancer, mutant KRAS and BRAF drive persistent MAPK pathway activity, often bypassing classical feedback controls. p38α and p38β isoforms are particularly implicated in inflammatory signaling and tumor cell survival, making them strategic drug targets. Targeted inhibitors enable precise dissection of roles for p38 in disease models and therapeutic studies [benchmarking review].

Mechanism of Action of SB 202190

SB 202190 is a pyridinyl imidazole compound that acts as a highly selective, ATP-competitive inhibitor of p38α and p38β MAPKs. It binds the ATP-binding pocket of the kinase domain, blocking access for ATP and preventing phosphorylation of downstream targets. The inhibitor displays IC₅₀ values of 50 nM (p38α) and 100 nM (p38β). It has a dissociation constant (K_d) of 38 nM for p38α, consistent with high-affinity binding in in vitro and cell-based assays [APExBIO]. SB 202190 does not significantly inhibit ERK1/2 or JNK MAPK isoforms at concentrations up to 10 μM, as determined by kinase selectivity panels [selectivity profile]. The result is potent, reversible suppression of p38-dependent signaling cascades leading to reduced pro-inflammatory cytokine expression, altered cell proliferation, and induction of apoptosis in sensitive cell lines.

Evidence & Benchmarks

• SB 202190 inhibits p38α kinase activity with an IC₅₀ of 50 nM (in vitro kinase assay, 25°C, pH 7.5) (APExBIO).
• SB 202190 displays high selectivity for p38α/β over JNK and ERK MAPKs, with less than 10% inhibition of these kinases at 10 μM (selectivity profile).
• In patient-derived colorectal cancer organoids, pharmacological inhibition of the MAPK pathway with p38 inhibitors modulates ERK phosphorylation and cell proliferation dynamics (Ponsioen et al., 2021).
• SB 202190 at 10 μM reduces TNF-α and IL-1β-induced cytokine expression in cultured macrophages by over 80% after 4 hours (review).
• In vascular dementia mouse models, SB 202190 administration (10 mg/kg, i.p., daily) reduces neuronal apoptosis and improves cognitive function within 14 days (APExBIO).

Applications, Limits & Misconceptions

SB 202190 is widely used as a tool compound in the following research areas:

• MAPK pathway dissection in cancer, inflammation, and neurodegeneration models.
• Cell-based apoptosis assays and proliferation studies.
• Organoid and assembloid systems for translational research [see comparison].
• Animal models of neuroprotection and vascular dementia [contrast with assembloid work].

This article extends previous overviews by integrating the latest organoid benchmarking data and highlighting SB 202190’s utility in systems with complex feedback signaling, as discussed by Ponsioen et al. (2021) [DOI]. Earlier reviews focus on the compound’s ATP-competitive selectivity and performance in cell culture [review]; here, cross-model translation and neuroprotection are detailed.

Common Pitfalls or Misconceptions

• SB 202190 is not a pan-MAPK inhibitor; it does not significantly inhibit ERK or JNK kinases at standard working concentrations.
• Water solubility is negligible; DMSO or ethanol are required for stock preparation.
• Long-term solution storage leads to loss of activity; fresh preparations are advised.
• Not all cell types respond identically: resistance may develop in cells with compensatory pathway activation (e.g., EGFR upregulation).
• Off-target effects at concentrations above 20 μM have been reported; always titrate for specificity.

Workflow Integration & Parameters

For in vitro studies, SB 202190 is typically used at 1–10 μM in cell culture, with DMSO as the solvent. For optimal solubility, dissolve at ≥10 mM in DMSO, warm to 37°C, and sonicate if necessary. Stock solutions should be aliquoted and stored at -20°C; thawed aliquots should be used immediately. In animal studies, dosing regimens range from 5–20 mg/kg (intraperitoneal), with efficacy observed in neuroprotection and inflammation models within 7–14 days.

Experimental design should consider potential feedback activation of upstream EGFR signaling, as MAPK pathway inhibition may relieve ERK-dependent negative feedback, resulting in paradoxical pathway reactivation [Ponsioen et al., 2021]. Combination with EGFR inhibitors may be necessary for robust suppression in cancer models with KRAS or BRAF mutations.

Conclusion & Outlook

SB 202190, provided by APExBIO, is a gold-standard, selective p38α/β inhibitor for dissecting MAPK pathway roles in inflammation, cancer, and neuroprotection research. Its nanomolar potency, ATP-competitive mechanism, and reproducible activity make it a reliable tool for both basic and translational studies. Future directions include expanded use in organoid systems, combination therapies targeting feedback networks, and integration into next-generation assembloid platforms [extended strategies]. For detailed protocols and batch information, visit the SB 202190 (A1632) product page.